Pacific Biosciences of California Inc (NASDAQ:PACB) Stock Price Settled at $3.35: What’s Resulting?
Stephens raised the price target for the Pacific Biosciences of California Inc (NASDAQ:PACB) stock to “an Overweight”. The rating was released on December 14, 2023, according to finviz. The stock was upgraded by UBS, who disclosed in a research note on November 17, 2023, from Neutral to Buy and set the price objective to $10. […]
Amprius Technologies Inc (AMPX) Stock Still Strong Despite Competition
ROTH MKM raised the price target for the Amprius Technologies Inc (NYSE:AMPX) stock to “a Buy”. The rating was released on January 11, 2024, according to finviz. The research report from Alliance Global Partners has initiated the stock to Buy, with a price target set at $10. The stock was initiated by H.C. Wainwright, who […]
Galmed Pharmaceuticals Ltd (GLMD) Stock Is Emerging from the Clouds
B. Riley FBR lowered the price target for the Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock from “a Buy” to “a Neutral”. The rating was released on May 22, 2020, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $14. In their research brief published […]
Does A Technical Metric Suggest That Protara Therapeutics Inc (TARA) Stock Is Ready To Rise?
Guggenheim raised the price target for the Protara Therapeutics Inc (NASDAQ:TARA) stock to “a Buy”. The rating was released on July 10, 2023, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $43. The stock was initiated by Cowen, who disclosed in a research […]
A New Look at Eyenovia Inc (EYEN) Stock’s Hidden Strategies
Northland Capital raised the price target for the Eyenovia Inc (NASDAQ:EYEN) stock to “an Outperform”. The rating was released on March 01, 2021, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price […]
Are Options A Good Investment Right Now? E.W. Scripps Co. (SSP) Stock
Wells Fargo lowered the price target for the E.W. Scripps Co. (NASDAQ:SSP) stock from “an Overweight” to “an Equal weight”. The rating was released on November 09, 2022, according to finviz. The research report from The Benchmark Company has reiterated the stock to Buy, with a price target set at $24. The stock was reiterated […]
Analyzing BigBear.ai Holdings Inc’s (BBAI) Stock earnings per share and revenue
Cantor Fitzgerald raised the price target for the BigBear.ai Holdings Inc (NYSE:BBAI) stock to “an Overweight”. The rating was released on January 09, 2024, according to finviz. The research report from H.C. Wainwright has initiated the stock to Buy, with a price target set at $4. In their research brief published March 28, 2022, Oppenheimer […]
Draganfly Inc (DPRO) Stock: Thought Concerns
The latest trade, Performances and Moving Averages give us the following Picture The firm’s stock price fluctuated 16.22% within the last five trades and 30.51% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -69.88% in the last 6 months […]
The latest Ouster Inc (OUST) Stock Technical Bulletin
Chardan Capital Markets raised the price target for the Ouster Inc (NYSE:OUST) stock from “a Buy” to “a Neutral”. The rating was released on April 03, 2024, according to finviz. The research report from Citigroup has downgraded the stock from Buy to Neutral, with a price target set at $1.70. The stock was downgraded by […]
A Tale from the Dusty Corner: Atara Biotherapeutics Inc (ATRA) Stock
Mizuho lowered the price target for the Atara Biotherapeutics Inc (NASDAQ:ATRA) stock from “a Buy” to “a Neutral”. The rating was released on November 09, 2023, according to finviz. The stock was downgraded by Citigroup, who disclosed in a research note on July 20, 2022, from Neutral to Sell and set the price objective to […]
